INTRODUCTION
Several randomised trials have demonstrated a significant reduction in colorectal cancer mortality following screening with guaiac faecal occult blood testing (FOBT) or flexible sigmoidoscopy on colorectal cancer mortality. 1 Flexible sigmoidoscopy has also been shown to reduce colorectal cancer incidence. 1 Therefore, colorectal cancer screening has been introduced in many countries. Concomitantly, low-dose aspirin is increasingly used in primary and secondary prevention of cardiovascular disease 2, 3 while recent evidence suggests that aspirin may also reduce colorectal cancer incidence and mortality. 2 If aspirin is as effective for colorectal cancer prevention as screening, it may be a game changer in how we approach the burden of colorectal cancer and other diseases at the same time. However, no head-to-head comparison of aspirin vs. colorectal cancer screening has been undertaken to allow reliable cost-effectiveness analyses for disease prevention and prioritisation of public health measures.
METHODS

Data sources and searches
We undertook a systematic literature review in adherence with the Cochrane collaboration 4 and PRISMA guidelines. 5, 6 We searched the COCHRANE central register (CENTRAL), Medline and EMBASE for randomised controlled trials on aspirin and screening published until 31 October 2015. For detailed search strategies, see Appendix S1. We searched separately for trials on aspirin, FOBT and flexible sigmoidoscopy, but the last search would also have identified eligible trials on colonoscopy, had they been published. One investigator (LE) excluded obviously irrelevant titles. Three investigators (LE, ØH and MK) independently reviewed all remaining abstracts. We obtained full text papers based on pre-defined inclusion and exclusion criteria (Appendix S1). Disagreement on eligibility was resolved by consensus. All eligible papers were read independently in full text, and the reference lists were examined for further relevant papers. We applied no language restrictions. Principal investigators of the included trials were contacted for further information if necessary. All original publications from the aspirin trials included in a recent meta-analysis 7 were read to evaluate study eligibility and quality.
Study selection
We included randomised trials reporting colorectal cancer mortality, colorectal cancer incidence, or both, with a minimum follow-up of 2 years and more than 100 included individuals. Trials on FOBT screening were only included if FOBT was offered repetitively, for example, at least twice (as recommended in guidelines), while flexible sigmoidoscopy could be once-only. 8 Colorectal cancer screening trials that included only high-risk populations (such as individuals with familial adenomatous polyposis or Lynch syndrome) were not included. In case of multiple publications from one trial, we included data from the publication with the longest follow-up.
Data extraction and quality assessment Primary study endpoints were colorectal cancer incidence (not including adenomas) and mortality. In some of the aspirin trials, colorectal cancer incidence and/or mortality were not reported in the original publications. [9] [10] [11] [12] We retrieved these data from meta-analyses of aspirin-trials 7, 13 or through personal communication with the study investigators. [14] [15] [16] [17] We also collected data on adverse effects, but because only some of the trials reported such events, a formal meta-analysis was not feasible. We assessed risk of bias due to random sequence generation, allocation concealment, blinding, incomplete data, and selective reporting in the aspirin studies. For the FOBT and flexible sigmoidoscopy screening trials, similar assessments were published a recent Cochrane meta-analysis by two of the investigators (MB and ØH).
1
Data synthesis and analysis
We identified no randomised trials on colonoscopy or trials which directly compared aspirin, FOBT-and flexible sigmoidoscopy screening. Thus, we performed indirect comparison meta-analyses (star-shaped network meta-analysis, see figure in Appendix S1). 18 We applied mixed treatment effect models based on a random effects model in a frequentist framework. 19, 20 The model incorporates a vector of mean estimates from the studies as well as a variance -covariance design-matrix for the randomised effect. We calculated predictive intervals (PrIs) for the indirect comparisons using the publicly available mvmeta program 21, 22 for Stata, 19 and PrIs were graphically presented in Forest plots. PrIs represent an interval within which the estimate of a future study is expected to be found. 23 We assumed a common heterogeneity across all interventions. As there are no direct comparison studies and thus, methodological heterogeneity between the study interventions assessments may be assumed, we present relative risks (RR) with PrIs instead of confidence intervals (CI). Inconsistency plots cannot be performed in a star-shaped network analysis. 19, 24, 25 Due to the small number of available studies in each treatment arm, we did not create Funnel plots to investigate publication bias. 19 We also performed pair-wise comparisons of FOBTand flexible sigmoidoscopy screening vs. no screening, and aspirin vs. placebo using a Mantel-Haenszel random effects model and report relative risks with 95% confidence intervals. We assessed heterogeneity or inconsistency (I 2 ) according to recommendations from the Cochrane collaboration. 4 In a post hoc analysis, we considered site of colorectal cancer (proximal or distal colon) and performed site-specific comparisons between aspirin, FOBT and flexible sigmoidoscopy. We defined cancers located in the rectum and sigmoid colon as distal and cancers proximal to the descending colon as proximal. Studies classified cancers located in the descending colon differently, and we followed the categorisation of the original trials. These differences should not affect our results because cancers in this part of the colon are rare. 26 We used STATA, version 13.1 (StataCorp LP, College Station, TX, USA) for all analyses.
Data items
There are some effect modifiers to mention in this context. There were differences in age; sigmoidoscopy was offered to individuals aged 50-74, FOBT to individuals aged 50-80 and aspirin to individuals 40 and above. Some of the aspirin trials demanded no history of cardiovascular disease, whereas others were secondary prevention after transitory ischaemic attack, previous cardiovascular history was not a part of exclusion/inclusion criteria for screening trials. All of the mentioned items affect competing causes of death. However, we believe that they do not infer with transitivity. An individual included in an aspirin trial could also have been included in a screening trial and vice versa. In addition, individuals treated with placebo could have dropped out due to adverse events, whereas that is implausible in a no screening arm.
RESULTS
We identified 10 937 titles including duplicates in the database searches. After the initial review, 539 abstracts were screened for eligibility and 62 publications were retrieved and read in full text. After exclusion of 45 irrelevant publications (Appendix S1), 17 publications from 15 randomised trials were included in the meta-analyses.
We identified no additional trials by searching the reference lists of the identified publications.
We did not identify any eligible trial on colonoscopy screening. Four trials compared FOBT screening with no screening, five trials compared flexible sigmoidoscopy screening with no screening, and six trials compared aspirin to placebo ( Table 2 ). Data on colorectal cancer incidence and colorectal cancer mortality were extracted from the original publications in the FOBT-and flexible sigmoidoscopy screening trials. In two of the aspirin trials, only colorectal cancer incidence was reported in the original publications. 14, 15 The principal investigators provided additional data on colorectal cancer mortality on our request. We included data on colorectal cancer incidence with longer follow-up than previously reported in one trial, 14 and unpublished data on colorectal cancer mortality in two trials. 16, 17 From the previously published meta-analyses of aspirin, we extracted data on colorectal cancer incidence from three additional trials, and colorectal cancer mortality from four additional trials (Table 1) . Follow-up ranged from 16 to 30 years for the FOBT studies, 11 to 26 years for the flexible sigmoidoscopy studies, and 18 to 23 years for the aspirin studies ( Table 1) .
Risk of bias
The randomised trials of FOBT-and flexible sigmoidoscopy screening were all rated as high quality and low risk of bias except from one small flexible sigmoidoscopy screening study that was rated as high risk of bias due to an inadequate randomisation procedure. 1 Assessments of the risk of bias in the aspirin trials are displayed in Table 2 .
Colorectal cancer incidence
There was no difference in colorectal cancer incidence reduction between aspirin and flexible sigmoidoscopy screening ( Flexible sigmoidoscopy screening did not reduce the incidence of proximal colorectal cancer whereas aspirin Bold values represent previously unpublished data * Previously unpublished data. † These two publications represent the same trial but one of the references is reporting cancer-specific mortality and the other one all-cause mortality. ‡ Input in analyses was made separate for the included studies according to Figure 1 in the publication. (Table 3 ). In the comparison analysis, aspirin was 37% more effective than flexible sigmoidoscopy in reducing colorectal cancer incidence (Table 3 ). In the distal colon, flexible sigmoidoscopy screening (RR 0.73; 95% CI 0.61-0.87) and aspirin (RR 0.77; 95% CI 0.58-1.04) reduced colorectal cancer incidence to the same extent (Table 3) .
Mortality. Site-specific colorectal cancer mortality was reported in one FOBT trial, 27 three flexible sigmoidoscopy trials, 1, 26, 28 and one aspirin study. 7 Neither FOBT nor flexible sigmoidoscopy screening reduced mortality from proximal colorectal cancer, while aspirin reduced mortality by 66% (Table 3) . Aspirin reduced mortality from proximal colorectal cancer by 64% compared to FOBT screening and by 63% compared to flexible sigmoidoscopy screening (Table 3) . FOBT screening and aspirin use did not affect mortality from distal colorectal cancer while flexiblex sigmoidoscopy screening led to 33% reduction (Table 3) .
We found no significant differences between FOBT-, flexible sigmoidoscopy screening and aspirin on distal colorectal cancer mortality (Table 3) .
DISCUSSION
Separate meta-analyses on effectiveness of screening 29 and aspirin, 30 respectively, have been published. However, this network meta-analysis is the first to compare the effects of colorectal cancer screening and aspirin on incidence and mortality from colorectal cancer. The magnitude of the effect of aspirin is comparable to that of FOBT-and flexible sigmoidoscopy screening, a finding with potentially large implications for policy making in cancer prevention. Our study also shows that flexible sigmoidoscopy screening is more effective than FOBT in reducing colorectal cancer incidence, a comparison that was earlier found to be non-significant. 1 Aspirin is more effective in preventing cancer in the proximal colon, while the benefit of flexible sigmoidoscopy screening is mainly in the distal colon. These site-specific findings should be interpreted cautiously, being based on fewer studies and may suffer from publication bias especially the post hoc publications of aspirin. However, the findings suggest a possible additive effect in combining the two interventions. As flexible sigmoidoscopy has important advantages compared with colonoscopy (less invasive, no sedation required, no oral bowel preparation) it may be more attractive for screening programmes and is currently rolled out in the UK as part of the bowel cancer screening programme from 2016. In addition, there is strong evidence for screening with flexible sigmoidoscopy as opposed to colonoscopy, where no large scale screening studies have been published. Hence, this study relies on the best available evidence of colorectal cancer screening effects. If the downside of flexible sigmoidoscopy (poor protection from proximal cancer) could be overcome by adding low-dose aspirin, the combination might be an attractive competitor to colonoscopy screening. Furthermore, due to other beneficial effects of aspirin (on cardiovascular disease, and other types of cancer), the combined strategy might reduce all-cause mortality, unlike any colorectal cancer screening strategy so far.
Previously, all three methods assessed by us have been shown to reduce colorectal cancer mortality as compared to no intervention. The evidence is strong for flexible sigmoidoscopy and FOBT because it is based on large scale, high-quality randomised trials designed for the specific endpoint with a low risk of bias. For aspirin, the evidence is weaker mainly because the trials were not primarily addressing the specific endpoint of colorectal cancer and the results are entirely based on post-trial follow-up (Table 2) . When we added updated data from the Physicians health study, 17 the effect of aspirin on colorectal cancer mortality was not statistically significant. Still the aspirin arm in total consists of about 38 000 patients whereas both FS and FOBT include more than 160 000 individuals in the intervention arm. Hence, the aspirin effect is estimated with less certainty causing wider confidence intervals calling for more cautious interpretation. In addition, pair-wise meta-analyses of both aspirin and FOBT showed significant heterogeneity whereas sigmoidoscopy did not. If aspirin is truly preventive at a magnitude similar to FOBT-and sigmoidoscopy screening, it is interesting from a health economy perspective. Although it may be premature to change practice, a head-to-head comparison trial on once-only flexible sigmoidoscopy vs. aspirin vs. a combination of both strategies seems highly motivated. Furthermore, such a trial would be of importance for general policy making because primary prevention with aspirin of both cancer and cardiovascular disease is not uncontroversial; some benefit-harm assessments indicate that it would be beneficial, 31 others state it being harmful 32 finally some support individualised assessments to improve treatment and prevention. 33 Finally, in clinical practice, a future question is how aspirin is best combined with other preventive strategies and if chemoprevention with aspirin indeed affects the performance of screening strategies. Transitivity, meaning that treatment A is similar when it appears in A vs. B and A vs. C trials, is an underlying assumption of network meta-analyses. One may argue that this criterion is not met in our analyses because aspirin is compared to placebo whereas flexible sigmoidoscopy and FOBT are compared to no screening. Placebo and no screening (usually considered unequal since placebo is effect-modifying whereas no screening is not) were in our comparison considered equal. However, for two reasons, we consider our comparison to be valid; first, a placebo effect on colorectal cancer incidence and mortality is biologically implausible. Second, individuals randomised to no screening might adopt a healthier lifestyle, and thus reduce their risk of colorectal cancer, hence being a control in a screening study may therefore affect your behaviour in a similar way as being included as a control in a pharmacological study. 34 Also the fact that colonoscopy screening rates were high for both aspirin and placebo groups (as high as 60% in WHS 15 ) is intriguing. However, screening rates were similar in the aspirin and placebo groups, and should therefore not affect our estimates.
To test the robustness of our results, we performed sensitivity analyses excluding the American aspirin trials (where colonoscopy screening was common; see Appendix S1). These analyses did not show any significant differences between the interventions, although the effect of aspirin itself increased. This may indeed indicate that there is an additive effect of aspirin to flexible sigmoidoscopy or colonoscopy but that the effect of aspirin itself decreases with high screening uptake. Also differences in the sampled populations may have impacted the results given that effectiveness can vary across populations by socioeconomic status. The fact that colonoscopy was common in some of the aspirin trials does not imply that some of the effect seen was due to colonoscopy (provided colonoscopy was equally distributed in individuals randomised to aspirin and placebo), but rather that the effect seen is additional to the effect of colonoscopy.
There are several open questions about the preventive effect of aspirin. None of the aspirin trials show a preventive effect during the first 8 years of follow-up (when the treatment was actually taking place). The duration of treatment and the doses vary between studies and there is no evidence of a dose-response association. 7 That we were not able to assess treatment duration is a limitation of this study (as well as all the previous). In the paper by Rothwell et al., 7 the number of patients and outcomes from different studies included are difficult to extract (except for colorectal cancer mortality which is available from Figure 1 in the referenced study 7 ). It is also not obvious why only four studies are included in this publication rather than the eight trials included in other publications on cancer mortality from the same group. 35 Methodologically, the analyses of aspirin and colorectal cancer prevention may be viewed as post hoc analyses because the trials were primarily designed for cardiovascular endpoints. However, a study to assess whether aspirin is protective of colorectal cancer would have been designed very similar, although the ideal setting would be the general population rather than persons with cardiovascular disease or risk factors. Despite being based on randomised trials, the evidence for the preventive effect of aspirin on colorectal cancer may be considered weak. However, the fact that several observational 36 studies show a protective effect of similar magnitude supports the theory that there is indeed a causal relationship. Another issue comparing screening strategies with a medical intervention is that it is not the screening (detection) per se that is effective in improving the future risk, it is instead the extended possibilities of early interventions and treatments that are causal, and their effectiveness may vary over time. This is a limitation of this study, but nevertheless the research question comparing screening to preventive medical strategies need to be addressed and currently no direct comparisons are available, thus this analysis is the best estimate available for now. Our analyses are based on broad search strategies and reporting of colorectal cancer outcome from general populations with no previously known increased risk of colorectal cancer. Beside the limitation that no head-tohead comparison trials were available, competing risks has not been taken into consideration in our analyses. This is, however, of little importance since deaths due to causes other than colorectal cancer is comparable in the different study arms within each trial (no effect on allcause mortality, see Appendix S1). The results should also be considered within the context that screening intensity was different in the screening trials and that the duration of aspirin randomisation as well as doses differed in the aspirin trials. Other limitations are that we could not compare aspirin to colonoscopy or FIT as there were no eligible trials of those two methodologies and that we could not assess adverse events due to lacking data in the publications.
Data from separate meta-analyses on colorectal cancer screening suggest that the range of adverse events in colonoscopy is 2-5 perforations and 5-14 major bleedings per 10 000 procedures. 29 Data on adverse effects of aspirin include gastrointestinal bleeding 14 per 10 000 person-years and intracranial bleeding, incidence 0.40% in individuals randomised to aspirin vs. 0.26% in controls. 30 
CONCLUSION
The effect of aspirin seems comparable to screening. The preventive effect is primarily seen in the proximal colon for aspirin, and in the distal colon for flexible sigmoidoscopy screening. Future studies addressing direct comparisons and possible additive effects of combining aspirin and flexible sigmoidoscopy would be of great interest.
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